Phosphatidylcholine
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatic and Hepatobiliary Disorders
Conditions
Hepatic and Hepatobiliary Disorders
Trial Timeline
Aug 1, 2015 → Jun 1, 2016
NCT ID
NCT02517385About Phosphatidylcholine
Phosphatidylcholine is a phase 3 stage product being developed by Sanofi for Hepatic and Hepatobiliary Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT02517385. Target conditions include Hepatic and Hepatobiliary Disorders.
What happened to similar drugs?
3 of 17 similar drugs in Hepatic and Hepatobiliary Disorders were approved
Approved (3) Terminated (5) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02517385 | Phase 3 | Completed |
Competing Products
20 competing products in Hepatic and Hepatobiliary Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ITF2357 | Biotrial | Phase 1 | 19 |
| GB1211 + Placebo | Comac Medical | Phase 1/2 | 18 |
| ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results) | Idorsia | Phase 1 | 23 |
| Olomorasib | Eli Lilly | Phase 1 | 29 |
| Simufilam | Cassava Sciences | Phase 1 | 19 |
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 40 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 35 |
| DS-3201b | Daiichi Sankyo | Phase 1 | 29 |
| Quizartinib | Daiichi Sankyo | Phase 1 | 29 |
| Quizartinib | Daiichi Sankyo | Phase 1 | 36 |
| Pexidartinib | Daiichi Sankyo | Phase 1 | 29 |
| Tivantinib + Tivantinib + Tivantinib + Tivantinib | Daiichi Sankyo | Phase 1 | 29 |
| Bocidelpar | Astellas Pharma | Phase 1 | 29 |
| fezolinetant | Astellas Pharma | Phase 1 | 29 |
| enzalutamide | Astellas Pharma | Phase 1 | 29 |
| ASP015K | Astellas Pharma | Phase 1 | 29 |
| ASP2215 | Astellas Pharma | Phase 1 | 29 |
| BPN14770 | Shionogi | Phase 1 | 29 |
| S-217622 | Shionogi | Phase 1 | 29 |
| Lemborexant | Eisai | Phase 1 | 29 |